Yamout, Bassem
Alroughani, Raed
Inshasi, Jihad
Farouk, Samar
Abdulla, Fatema
Al-Jarki, Namareq Y.
Alasmi, Abdulla
Al Fahad, Sarmad
Alkhabouri, Jaber
Al-Saffar, Khalid
Benedetti, Beatrice
Canibano, Beatriz
Deleu, Dirk
Hassan, Ali
Sarathchandran, Pournamy
Shatila, Ahmed
Abouelnaga, Mohammad
Thakre, Mona
Szolics, Miklos
Boshra, Amir
Article History
Received: 18 June 2024
Accepted: 22 July 2024
First Online: 3 August 2024
Declarations
:
: This article arose from discussions at meetings funded by Merck Serono Middle East FZ Ltd, an affiliate of Merck KGaA. Additionally: Dr Khalid Al Saffar is engaged as a speaker with pharmaceutical companies and is a member of advisory committees of Abbott, Novartis, Lilly, Pfizer, Merck, Sanofi, Janssen, Bayer, Biogen, Julfar, Alhikma and GlaxoSmithKline. Dr Pournamy Sarathchandran received speaker honoraria from Merck, Novartis, Roche, and Dr Ahmed Osman Shatila reports honoraria for lectures (Sanofi-Genzyme, Merck, Genpharm, Roche, Novartis, Boehringer Ingelheim, Biologix) and for advisory boards (Sanofi-Genzyme, Roche, Novartis, Pfizer, Biologix); educational conferences travel and registration and hotel accommodation has been sponsored by Sanofi-Genzyme, Merck, Genpharm, Roche, Novartis, Biologix. Dr Amir Boshra is an employee of Merck Serono Middle East FZ Ltd, Dubai, UAE, an affiliate of Merck KGaA. Dr Raed Alroughani received honoraria as a speaker and for serving in scientific advisory boards from Bayer, Biogen, Merck, Novartis, Roche, and Sanofi. Dr Samar Farouk received honoraria as a speaker and for serving in scientific advisory boards from Bayer, Biogen, Merck, Novartis, Roche, and Sanofi. Dr Bassem Yamout has received honoraria for lectures and advisory boards from Bayer, Biogen, Genpharm, Merck, Novartis, and Sanofi, and has received research grants from Bayer, Biogen, Merck, Novartis, and Pfizer. Dr Dirk Deleu has served on Advisory Boards of Merck, Novartis, Biologix, Roche and Sanofi and is a member of MENACTRIMS. Dr Beatriz Canibano has received travel, speaker and consultant honoraria from Merck, Novartis, Biologix, Roche and Sanofi. Dr Abdullah Al-Asmi received honoraria for serving on scientific advisory boards from Merck, Novartis, Roche, and Sanofi, and also received travel reimbursement from, Biologix, Sanofi, Merck, Roche, Bayer and Novartis. Drs Jihad S Inshasi, Sarmed Alfahad, Ali Hassan, Miklos Szolics, Jaber Alkhabouri, Beatrice Benedetti, Fatema Abdulla, Dr Namareq Alarji, Mohammad Abouelnaga, and Mona Thakre reported no other dualities of interest.
: This narrative review is based on previously conducted studies and the clinical expertise of the authors in treating patients with RMS. No new clinical studies were performed by the authors. No patient-specific efficacy or safety data were reported. Therefore, institutional review board (IRB)/ethics approval was not required.